Danaher (DHR) Stock Forecast & Price Target

Danaher is viewed positively because its post-Veralto portfolio is more focused, higher quality, and supported by strong positions in bioprocessing, life sciences, and diagnostics, where core growth is already improving despite conservative 2027 framing. Recent results reinforced that view: 3Q26 revenue was $6.55B, core growth was 3.0% and 5.5% ex-respiratory, adjusted operating margin reached 29.0%, EPS was $2.11, and free cash flow was $1.6B, showing both earnings power and cash generation. Management’s 4% to 5% initial 2027 core growth view, along with mid-teens bioprocess orders, resilient consumables demand, and the prospect of accretive tuck-in acquisitions, suggests durable upside as end-market recovery broadens.

Danaher is facing a weaker fundamental backdrop as bioprocess equipment demand has not yet benefited from reshoring, Life Sciences instrument spending continues to decline, and China diagnostics remains a drag even as pricing headwinds ease. The company’s reliance on M&A also looks less supportive than before, because several recent Life Sciences acquisitions have failed to meet expectations and investors no longer extend the benefit of the doubt on announced deals. With risks tied to slower spending by biopharma companies, lower government research funding, and weaker hospital and clinic demand, margins and growth could disappoint if current levels of macro softness persist.